Trump Imposes 100% Tariffs on Pharmaceutical Imports

The President issued a proclamation under Section 232 of the Trade Expansion Act of 1962 imposing 100% tariffs on imports of patented pharmaceuticals and pharmaceutical ingredients, citing national security concerns. The Commerce Department found that approximately 53% of patented pharmaceuticals are currently imported, raising concerns about domestic supply chain vulnerabilities.

The action, coordinated with increased tariffs on aluminum (50%) and steel/copper (25%), represents the most aggressive trade measures in recent history. The pharmaceutical tariffs could significantly impact drug pricing and supply chains that rely on foreign manufacturing.

Pharmaceutical manufacturers and importers should assess their supply chain exposure and evaluate tariff mitigation strategies as implementation timelines approach.